New U.S. tariffs on generic drugs could pressure drugmakers and influence pharmaceutical ETFs. Here's what investors should watch.
Zacks
More News
Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
Smart Beta ETF report for PJP
Zacks
Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?
Sector ETF report for PJP
Zacks
Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
Smart Beta ETF report for PJP
Zacks
Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?
Sector ETF report for PJP
Zacks
Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
Smart Beta ETF report for PJP
Zacks
Why Did CANF Stock Soar 25% Today?
The company said its trial to study the treatment of patients with advanced pancreatic ductal adenocarcinoma met its primary endpoint.
Stocktwits
Merck Splits Oncology, Specialty Operations To Brace For Keytruda Patent Loss – Overhauls Leadership To Drive Growth
The drugmaker said it will reorganize its human health segment into two separate units in an effort to better position its portfolio for the years ahead.
Stocktwits
Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?
Sector ETF report for PJP
Zacks
FDA Commissioner Raises Concerns About US Pharma Lagging Behind China In Drug Development
Marty Makary, in an interview with CNBC, further called for reforms that could streamline the process for starting trials on new treatments.